Project Grant HT94252310088
Award Date
3/1/23
Completion Date
2/28/25
Dollars Obligated
$297K
Federal Agency
Defense Health Agency
Federal Grant Program
12.420
Assistance Type
Project Grant
Place of Performance
Australia
Similar Awards
The University of Queensland in Australia was awarded a $520,011 Project Grant from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant will support research from August 1, 2022 to July 31, 2025 on a novel mediator of cholangiocarcinoma that has potential as a diagnostic and treatment target. The Military Medical Research and Development program aims to transform military and public health through innovative biomedical...
The Defense Health Agency awarded a $744,997 Project Grant to the University of Queensland in Australia under the Military Medical Research and Development program (CFDA 12.420). This grant, titled "DISCOVERING THERAPEUTIC VULNERABILITIES OF CIRCULATING MELANOMA CLUSTERS," provides funding for the university to conduct cutting-edge biomedical research on melanoma from June 1, 2024 through May 31, 2027. The University of Queensland, a leading research institution in Australia, has an...
The University of Queensland in Australia was awarded a $2,383,881 Project Grant from the Department of the Army Medical Command on September 15, 2022 to complete work by September 14, 2026. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform health care for service members and the public through innovative and impactful research, as well as investigate medical solutions for the...
The University of Queensland in Australia was awarded a $744,744 USD project grant from the Department of the Army Medical Command's Military Medical Research and Development program (CFDA 12.420). The grant will fund a research project titled "Understanding the Role of Immature Myeloid Cells in Early Melanoma Establishment" from September 30, 2022 to September 29, 2025. Through this funding, researchers at The University of Queensland will investigate the role of immature myeloid...
The University of Queensland in Australia was awarded a $1,488,596 Project Grant from the Department of the Army Medical Command to support melanoma research from September 2022 through September 2025. The grant is funded through the Military Medical Research and Development program (CFDA 12.420), which aims to transform military and public health care through innovative biomedical research solutions for battlefield medicine and other health issues. Under this award, The University of Queensland...
The U.S. Department of Defense's Defense Health Agency has awarded a $466,234 Project Grant to the University of Queensland in Australia to conduct "PROOF-OF-CONCEPT STUDIES FOR A NOVEL IMMUNOTHERAPY FOR TRIPLE-NEGATIVE BREAST CANCER AND COMPANION DIAGNOSTIC." This research grant, funded through the Military Medical Research and Development program (CFDA 12.420), aims to develop innovative treatments and diagnostic tools to improve care for military service members, veterans, and their...
This federal Project Grant award of $1,120,707 from the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420) is supporting advanced biomedical research by the University of Queensland in Australia. The project aims to develop a first-in-class calcium channel inhibitor for the treatment of advanced metastatic prostate cancers that are resistant to next-generation antiandrogen therapy. The grant has a performance period from July 1,...
The Department of Defense's Defense Health Agency awarded a $1,205,784 Project Grant to Queensland University of Technology (QUT) under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "ACCELERATING TRANSLATION OF A NOVEL METAP2 INHIBITOR IN TREATMENT-RESISTANT AND AGGRESSIVE-VARIANT PROSTATE CANCER," runs from July 1, 2024 to June 30, 2027. The project aims to accelerate the translation of a novel MetAP2 inhibitor therapy for treating...
This $1,580,000 Project Grant awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program supports research to develop noninvasive methods for predicting inflammatory bowel disease exacerbations at the University of California, San Diego (UCSD). The 3-year project, running from March 2025 to February 2028, will utilize multiomics approaches to investigate biomarkers that can be detected through non-invasive testing to anticipate disease...
This $1,214,449 federal Project Grant was awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program. The grant will fund the development and translation of a multimodal therapeutic agent and medical countermeasure for the treatment of military-related toxic exposures. The awardee, Queensland University of Technology (QUT) in Australia, will lead this 3-year research effort from September 1, 2024 to August 31, 2027. QUT is a prominent...